Allena Pharmaceuticals Secures $25 Million Series B Financing
“The positive response and level of interest we have received from investors is a great reflection of our seasoned management team, the market opportunity and the unmet need that ALLN-177 meets in the treatment of hyperoxaluria,” said Alexey Margolin, ...
Business Wire (press release) - Thu, 04 Dec 2014 04:00

Biotech partners at Allena fund a march toward PhIII with $25M venture round
FierceBiotech - Thu, 04 Dec 2014 05:53

Alnylam Announces Planned Departure of Chief Business Officer, Laurence ...
... for the treatment of AAT deficiency-associated liver disease; ALN-TMP targeting TMPRSS6 for the treatment of beta-thalassemia and iron-overload disorders; ALN-GO1 targeting glycolate oxidase (GO) for the treatment of primary hyperoxaluria type 1 ...
Business Wire (press release) - Fri, 19 Dec 2014 04:56

Alnylam Pharmaceuticals Inc.: Alnylam Elects Michael W. Bonney to Its Board of ...
... for the treatment of AAT deficiency-associated liver disease; ALN-TMP targeting TMPRSS6 for the treatment of beta-thalassemia and iron-overload disorders; ALN-GO1 targeting glycolate oxidase (GO) for the treatment of primary hyperoxaluria type 1 ...
The Wall Street Transcript - Thu, 18 Dec 2014 04:56



Newton biotech with drug to treat recurring kidney stones gets $25M
The money will allow the company to complete a Phase 2 trial, and start a Phase 3 trial, of what could become the first pill to treat hyperoxaluria, a disease that can lead to kidney stones, chronic kidney disease, end-stage renal disease and dialysis.
Boston Business Journal (blog) - Thu, 04 Dec 2014 10:40

Dicerna Announces the Appointment of Theodore T. Ashburn, MD, Ph.D. to ...
The Company has already made significant progress on both its platform and on several of its programs, most notably its DCR-MYC and DCR-PH1 programs for various cancers and primary hyperoxaluria type 1, respectively.” Dicerna also today announced it ...
MarketWatch - Wed, 17 Dec 2014 15:36

East Coast Biotech Roundup: Unum, RaNA, Maxwell, Biogen, & More
Allena will use the cash to get its prospective treatment for hyperoxaluria—a metabolic condition that can cause kidney stones and even kidney failure—into Phase 3 testing. Allena recently began Phase 2 trials for the drug, ALLN-177, and plans to ...
Xconomy - Fri, 05 Dec 2014 06:37

Alnylam Introduces Pipeline Growth Strategy for RNAi Therapeutics in Three ...
... for the treatment of AAT deficiency-associated liver disease; ALN-TMP targeting TMPRSS6 for the treatment of beta-thalassemia and iron-overload disorders; ALN-GO1 targeting glycolate oxidase (GO) for the treatment of primary hyperoxaluria type 1 ...
Digital Journal - Fri, 12 Dec 2014 04:00

Alnylam Initiates ENDEAVOUR Phase 3 Clinical Trial with Revusiran (ALN ...
... including preeclampsia; ALN-GO1 targeting glycolate oxidase (GO) for the treatment of primary hyperoxaluria type 1 (PH1); ALN-HDV targeting the hepatitis delta virus (HDV) genome for the treatment of HDV infection; ALN-PDL targeting programmed ...
Business Wire (press release) - Thu, 11 Dec 2014 13:00


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014